Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

Resignation of Chief Financial Officer

On January 2, 2020, Michael MacLean, Chief Financial Officer of Akcea Therapeutics, Inc. (the "Company") delivered to the Company a 90-day notice of resignation from his position as Chief Financial Officer of the Company. Mr. MacLean's resignation is effective April 1, 2020.

In accordance with the letter agreement dated October 11, 2019 (the "Letter Agreement") entered between Mr. MacLean and the Company, Mr. MacLean will be entitled to receive medical benefit continuation, a lump sum severance payment equal to 12 months of his base salary, and an amount equal to his target annual cash performance bonus for 2019.

The description of the Letter Agreement set forth above is qualified in its entirety by reference to the full and complete terms set forth in such agreement, which was filed as an exhibit to the Current Report on Form 8-K filed on October 17, 2019.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses